Related references
Note: Only part of the references are listed.Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
Shahin Jamal et al.
JOURNAL OF RHEUMATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
Andrea Pagan et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2020)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective
Dipti M. Karamchandani et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
Caroline Prieux-Klotz et al.
TARGETED ONCOLOGY (2017)
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Viktoria Bergqvist et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
α-CTLA-4 mAb-associated panenteritis -: A histologic and immunohistochemical analysis
Darryl A. Oble et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Raymond M. Wong et al.
INTERNATIONAL IMMUNOLOGY (2007)
Share Paper
